Connect with us


“It’s given Bailey his quality of life back – we never want to take that away from him”



Medical cannabis has changed Bailey's life

Bailey Williams suffered hundreds of seizures a day before cannabis oil gave him his life back – but his family is forced to raise thousands to fund it. Bailey’s mum, Rachel Rankmore tells Sarah Sinclair why they won’t stop fighting for NHS access to the drug.

When the coronavirus lockdown came into force earlier this year, Rachel Rankmore and her husband Craig Williams’ first thought was whether they would still be able to import the cannabis oil that gives their son a better quality of life.

The second was how they would continue to raise the £1,700 each month to fund the prescription.

Bailey Williams, 19, has a rare form of epilepsy, Lennox Gestaut Syndrome.

He was born a healthy baby, but at the age of two and a half his parents woke in the night to the sound of him choking – Bailey was experiencing his first fit.

Medics initially diagnosed a febrile convulsion, but over time the seizures became more frequent – and severe – and Bailey was put on anti-epileptic drugs.

“Your whole world comes crashing down,” says Rachel, 44, a full-time carer for Bailey at their home in Cardiff.

“We were first-time parents and you imagine that you’re going to have this perfect family.

“Bailey had to stop going to nursery, the seizures became more violent and progressed into drop seizures, absence seizures, myoclonic jerks, and partial seizures happening throughout the day and night.

“He had to wear a crash helmet and afterwards would be left bedridden or in need of a wheelchair.”

Bailey tried over 20 antiepileptic drugs, all of which failed to stop the seizures and left him experiencing extreme side effects, including hair and weight-loss and head-to-toe rashes.

“He had a really traumatic time on the medicines that were supposed to make him well and they just weren’t working,” continues Rachel.

“The quality of life was just awful for the whole family.”

Then the couple’s second son Ross, born four years later, was also diagnosed with a less severe form of epilepsy as a toddler.

Rachel and Craig made the decision to stop his medication, which was making him fall asleep at school, and thankfully Ross, now 14, has been seizure-free since.

But both boys have been left with learning difficulties and dyslexia as a result of their condition.

The family went onto try and control Bailey’s epilepsy through a ketogenic diet, which left him at risk of diabetes, and even explored brain surgery which he wasn’t a candidate for.

After what Rachel describes as ‘years of hell’, Bailey was given a vagus nerve stimulation, aged seven, which is supposed to prevent seizures by sending regular, mild pulses of electrical energy to the brain via the vagus nerve.

Although it alleviated some of his symptoms, Bailey being blue-lighted to hospital in an ambulance was still a weekly occurrence.

At their lowest point, with Bailey enduring another stint in the High Dependency Unit at the University Hospital of Wales, doctors told Rachel and Craig they had nothing left to try.

“The doctor said we have given him everything we can…we don’t know if he’s going to wake up at all and we’ve got nothing left to try,” she says.

“We just felt total despair.”

But they kept looking for other options, and came across the story of Charlotte Figi – the American youngster who helped popularise CBD use for the treatment of her epilepsy.

Charlotte’s Web CBD, named after the girl was founded in 2011. And when a friend of Rachel’s discovered a place in the UK was selling it, around six years ago they didn’t hesitate.

Rachel says: “We got in the car and went straight to buy our first bottle of Charlotte’s Web. That was a major turning point for Bailey, it gave him his life back.”

The drops seizures stopped, he became more vocal and was able to start learning again at a special needs school.

She adds: “He was just like an average boy, it was absolutely amazing.”

But just over two years ago Bailey started to plateau on Charlotte’s Web – which is not a full extract cannabis oil – and began deteriorating rapidly.

At one point he was having hundreds of seizures a day.

Around the same time, Hannah Deacon was fighting for access to cannabis for her son Alfie.

After seeing her story on This Morning, Rachel and Craig joined other parents in the End our Pain mission to change UK law. Alfie became the first patient in the UK to receive a permanent cannabis licence and is now only one of less than patients with an NHS prescription.

But despite being a candidate for medical cannabis Bailey’s doctors wouldn’t prescribe it.

Guidelines published by the National Institute for Health and Care Excellence (NICE) last year recommend Epidyolex – a drug containing CBD with clobazam – to be offered as an option used to treat seizures associated with Lennox-Gastaut syndrome in children aged two years and older.

Rachel says they were offered Epidyolex but had heard from other parents it had failed to be effective and instead turned to a private neurologist in London, who prescribed Bailey full extract cannabis oil.

The starting dose cost £2,500 and to reduce the cost of thousands more in fees incurred by importing the drug from Holland, Rachel criminalised herself, travelling to the country in person to collect Bailey’s medicine.

They now rely on donations through the Mission for Bailey’s Shakes fundraising page – initially set up to raise £55,000 to buy an EEG machine for the hospital –  supporters have continued to raise money to cover the costs of Bailey’s prescription, becoming “close friends” along the way.

“Bailey’s quality of life is amazing, he’s able to interact and tell us what he wants to do, he wants his own home and he wants to drive and he’s coming up with all these things that he wants to do in the future, which is incredible and quite emotional because it’s something we never thought we’d see,” says Rachel.

But Rachel and Craig, who still take turns to sleep next to Bailey every night in case he has a seizure, fear what the future looks like for their son if cannabis oil is not made available on the NHS.

“It’s a treatment, it’s not a miracle cure but it’s given Bailey his quality of life back and we never want to take that away from him, that would be cruel,” she continues.

“But we can’t sustain the level of costs indefinitely – what happens when we’re not here?”

The coronavirus lockdown has meant they have been unable to hold fundraising events, such as fairs, golf tournaments and bike rides which keeps the Mission for Bailey’s Shakes fund topped up and have now switched to a cheaper UK supplier.

The struggles of the previous months have made the family more determined in the fight to see cannabis oil available to patients on the NHS.

“It would be amazing for us to have an NHS prescription so we can just live our lives like everyone else, without having to think where the next lot of money was coming from,” says Rachel.

“It would be such a weight off our shoulders to know that we can plan a future for Bailey, to be able to stop fighting and fundraising and just enjoy our son being well.”

She adds: “This is why we need to keep fighting to make sure our children are safe and well on the medicine that works for them.”

NICE has acknowledged the need for more research into the use of medical cannabis and supports NHS England’s call to collect evidence from randomised controlled trials and observational studies.

But the guidelines state that until there is clear evidence of the safety and effectiveness of cannabis-based medicinal products, specialist doctors need to consider individual patient circumstances and risks and benefits in choosing treatments.

As most cannabis-based medicinal products are currently unlicensed, doctors must follow General Medical Council guidelines of prescribing.

A spokesperson for Cardiff and Vale University Health Board, said: “Our clinicians always act in the best interests of patients and put them at the centre of everything we do. We will continue to work with Bailey and his family to best manage his condition.”

Donate here


Australia lists first subsidised medical cannabis drug

Epidyolex has become the first medical cannabis product to be subsidised by the Australian Government.



Epidyolex is the first medical cannabis product to be subsidised by the Australian Government

The epilepsy drug, Epidyolex has become the first medical cannabis product to be subsidised by the Australian Government.

Australians living with the rare form of epilepsy known as Dravet syndrome, will now have access to the cannabis-derived drug via the country’s Pharmaceutical Benefits Scheme (PBS) for the first time.

As of 1 May, 2021, Epidyolex, which contains CBD, is listed on the PBS for patients with the treatment-resistant condition, to be used in combination with at least two other anti-epileptic medicines. 

Epidyolex is only the second medicinal cannabis drug registered for supply in Australia, and the first one to be subsidised by the Government on the PBS.

Dravet syndrome is a rare, genetic epileptic encephalopathy that gives rise to seizures which don’t respond well to the standard medications.

It is estimated that around 116 patients each year will benefit from the listing of Epidyolex, who might otherwise pay more than $24,000 per year for the treatment. 

They will now pay only $41.30 per script or $6.60 if they have a concession card.

According to a report by FreshLeaf Analytics published last year, there are now around 30,000 medical cannabis patients in Australia with “record-numbers” of doctors prescribing.

But as prescriptions are not covered under the PBS, they remain costly compared to conventional medicines and out of reach for many.

In a statement announcing the listing of Epidyolex, Australian Health Minister Greg Hunt said the Government’s commitment to ensuring patients can access affordable medicines “remains rock solid”. 


Continue Reading


Experts to explore the role of medical cannabis in women’s health

A line-up of leading experts will discuss how cannabis medicines can play a vital role in women’s health.



Many women are still unaware of female-specific health conditions such as pelvic inflammatory syndrome (PIS) or vulvodynia

Leading pain specialist, Dr Sally Ghazaleh will join a line-up of experts to discuss how cannabis medicines can play a vital role in women’s health.

The first of a four-part webinar series, taking place on Wednesday 12 May, will focus on the experience’s of women who have not felt supported by the current healthcare system – and how cannabis has helped them find relief from their conditions.

Dr Sally Ghazaleh, a pain specialist at Integro Medical Clinics, will join Sarah Higgins, clinical nurse specialist and women’s health lead at Cannabis Patient Advocacy Support Services (CPASS), alongside endometriosis patients Abby Hughes, outreach chair of PLEA (Patient-Led Engagement for Access) and Laura, author of The Endomonologues blog.

Dr Sally Ghazaleh

Dr Sally Ghazaleh is a pain management specialist

Aimed at patients, clinicians and the general public the webinar series, hosted by Cannabis Health, Integro Clinics and CPASS, aims to discuss the application of cannabis medicines in the management of complex female health conditions.

It will also highlight some of the wider issues and gender inequalities played out in the modern medical model.

Studies have shown that women’s pain is not acted on as quickly and is more likely to be dismissed than men’s, while many conditions can present differently in women than in men and therefore take longer to diagnose.

Many women are still unaware of female-specific health conditions such as pelvic inflammatory syndrome (PIS) or vulvodynia and can live with the symptoms for many years before they are correctly diagnosed and treated.

Some patients are now reporting that they have found cannabis medicines to be helpful in the management of their health conditions.

Dr Ghazaleh, a consultant at Whittington Hospital and the National Hospital of Neurology and Neurosurgery in London, joined Integro Clinics as a prescriber of medical cannabis in January. 

She specialises in managing patients with a wide range of pain conditions and has a particular interest in bladder and abdominal pain in women, and women’s health in general.

The free webinar will take place on Wednesday 12 May at 7pm.

The event is hosted by Cannabis Health, Integro Medical Clinics and CPASS, sign up for free here

If you would like further information, or to make an appointment for a medical consultation with Dr Sally Ghazaleh please contact Integro Clinics:  


Twitter: @clinicsintegro


Continue Reading


Cannabis treatment to be trialled for common pet health issue

Trials of a synthetic cannabinoid treatment for common eye problems in dogs have been given the green light.



close up of dog
Eye ulcers are one of the most common health problems in dogs

Trials of a cannabis-derived treatment which could rid dogs of common and potentially blinding eye ulcers, have been given the go-ahead.

Tetra Bio-Pharma will continue with clinical trials on its synthetic cannabinoid products in the hope of finding an easy-to-use medication for pets with the painful condition.

Eye ulcers are one of the most common health problems in dogs and, if left untreated, can lead to the loss of an eye.

The condition is particularly common among a number of breeds which have gained in popularity in recents years, including pugs, bulldogs and West Highland terriers.

Initial symptoms include a red and aggravated eye and the condition often needs to be treated by a vet.

Progress has been slowed due to the Covid-19 pandemic but now the company is looking to forge ahead with the first-of-its-kind trial after receiving authorisation from the Veterinary Drugs Directorate of Health Canada.

The company is also engage in developing a treatment for acute respiratory distress syndrome (ARDS) which could eventually be used to treat people suffering with the coronavirus.

The trials of PPP-003v, Tetra’s proprietary veterinary ocular formulation for treating ocular pain and inflammation in companion animals, could see Tetra find a way into a market expect to be worth over $220 million by 2026.

Dr Guy Chamberland, CEO and CRO of Tetra Bio-Pharma, said: “The PPP-003 program, including PPP-003v, represents a significant opportunity for Tetra since there is a substantial unmet medical need for painful inflammatory eye disease.”

He added: “We are pleased with this regulatory authorisation and the ability to re-activate the trial.

“While the active pharmaceutical ingredient used in the PPP-003v drug formulation is the same as the one used in ARDS-003, Tetra’s innovative immunomodulator drug concurrently being developed for Covid-19, there is a major difference with how the drug is delivered.

“PPP-003v is intended to be used as a topical medication and is delivered as a sterile eye drop and ointment, while ARDS-003 is a sterile injectable nano-emulsion finished drug product.”

Continue Reading